Teladoc Poised for Growth Despite Stock Drop; Pfizer Looks Beyond COVID with New Drugs and Seagen Deal
-
Teladoc is a leading telemedicine provider whose stock price has dropped recently, but telemedicine adoption is growing and Teladoc is well-positioned for future growth.
-
Teladoc has been working on improving its bottom line, reducing losses over the past year. Revenue and memberships are also substantially higher than 5 years ago.
-
Pfizer made huge profits from its COVID-19 products, but revenue has now dropped off. It recently had a string of new drug approvals that will help offset this gap.
-
Pfizer acquired cancer specialist Seagen and has a promising pipeline that will drive future revenue and earnings growth.
-
Pfizer's valuation metrics like P/E ratio and dividend yield make it an attractive stock for long-term investors.